Cantor Fitzgerald Forecasts OTCMKTS:ZLDPF FY2026 Earnings

Zealand Pharma A/S (OTCMKTS:ZLDPF - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Zealand Pharma A/S in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will post earnings of $7.74 per share for the year. The consensus estimate for Zealand Pharma A/S's current full-year earnings is ($2.19) per share.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.10. Zealand Pharma A/S had a negative return on equity of 15.24% and a negative net margin of 1,725.03%. The firm had revenue of $1.14 million during the quarter, compared to analyst estimates of $248.61 million.

Separately, William Blair raised Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a research report on Friday, March 7th.

Zealand Pharma A/S Stock Down 5.5%

Zealand Pharma A/S stock traded down $4.05 during midday trading on Thursday, reaching $70.08. The stock had a trading volume of 1,525 shares, compared to its average volume of 923. Zealand Pharma A/S has a 12 month low of $57.97 and a 12 month high of $141.74. The company has a market capitalization of $4.98 billion, a P/E ratio of -29.69 and a beta of 0.74. The company has a fifty day moving average price of $66.60 and a two-hundred day moving average price of $85.37. The company has a current ratio of 35.49, a quick ratio of 35.49 and a debt-to-equity ratio of 0.03.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.